FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2230151041> ?p ?o ?g. }

• W2230151041 endingPage "1553" @default.
• W2230151041 startingPage "1545" @default.
• W2230151041 abstract "Tyrosine kinase inhibitors (TKI) are the initial treatment for majority of newly diagnosed patients with chronic myelogenous leukemia (CML) in chronic phase (CP) and are associated with marked improvement in hematological, cytogenetic, molecular response and survival rates compared with other therapies. In this review, we summarize the evidence of TKI efficacy for patients with newly diagnosed CP‐CML. Six trials at low risk of bias evaluating TKIs as an initial treatment in adults with newly diagnosed CP‐CML and enrolling 2,456 patients were included. Follow‐up times ranged from a median of 3 months to 5 years. Direct comparison showed statistically higher rates of major molecular response (MMR ≤ 0.1% IS ) achievement with second‐generation TKIs at 12 months which was sustained throughout treatment period. Bayesian mixed‐treatment comparison (MTC) analysis demonstrated superiority of both nilotinib and dasatinib over imatinib in terms of efficacy. Nilotinib was associated with higher deeper molecular responses (MR 4.5 ≤ 0.0032% IS ) at 60 months than dasatinib but no difference in MMR. The differences between nilotinib and dasatinib are likely clinically trivial. Among TKIs, nilotinib was found to have the best survival profile. Both nilotinib and dasatinib are associated with significantly better MMR compared to imatinib that is sustained over 60 months. This analysis shows that new‐generation TKIs are not only showing faster response but also maintaining a more potent one through longer follow‐up period. It is important to note out that MTC is not a substitute for well‐conducted RCTs investigating direct comparisons." @default.
• W2230151041 created "2016-06-24" @default.
• W2230151041 creator A5008422091 @default.
• W2230151041 creator A5019711135 @default.
• W2230151041 creator A5030769154 @default.
• W2230151041 creator A5031021734 @default.
• W2230151041 creator A5032260744 @default.
• W2230151041 creator A5035100026 @default.
• W2230151041 creator A5054802858 @default.
• W2230151041 creator A5059366804 @default.
• W2230151041 creator A5061219299 @default.
• W2230151041 creator A5064251341 @default.
• W2230151041 creator A5085875893 @default.
• W2230151041 date "2015-10-28" @default.
• W2230151041 modified "2023-10-17" @default.
• W2230151041 title "Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison" @default.
• W2230151041 cites W1490900965 @default.
• W2230151041 cites W1963599260 @default.
• W2230151041 cites W1967046314 @default.
• W2230151041 cites W1968747503 @default.
• W2230151041 cites W1969672788 @default.
• W2230151041 cites W1981809014 @default.
• W2230151041 cites W1997360163 @default.
• W2230151041 cites W2021648831 @default.
• W2230151041 cites W2024813313 @default.
• W2230151041 cites W2052054991 @default.
• W2230151041 cites W2052840793 @default.
• W2230151041 cites W2057206328 @default.
• W2230151041 cites W2058216377 @default.
• W2230151041 cites W2061440903 @default.
• W2230151041 cites W2064831267 @default.
• W2230151041 cites W2068977368 @default.
• W2230151041 cites W2070067474 @default.
• W2230151041 cites W2072834954 @default.
• W2230151041 cites W2097799776 @default.
• W2230151041 cites W2098923148 @default.
• W2230151041 cites W2113144077 @default.
• W2230151041 cites W2126930838 @default.
• W2230151041 cites W2128738046 @default.
• W2230151041 cites W2129977554 @default.
• W2230151041 cites W2143939343 @default.
• W2230151041 cites W2147109509 @default.
• W2230151041 cites W2147270075 @default.
• W2230151041 cites W2156145496 @default.
• W2230151041 cites W2169961966 @default.
• W2230151041 cites W2314924484 @default.
• W2230151041 cites W2576440140 @default.
• W2230151041 doi "https://doi.org/10.1002/ijc.29889" @default.
• W2230151041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26455714" @default.
• W2230151041 hasPublicationYear "2015" @default.
• W2230151041 type Work @default.
• W2230151041 sameAs 2230151041 @default.
• W2230151041 citedByCount "13" @default.
• W2230151041 countsByYear W22301510412016 @default.
• W2230151041 countsByYear W22301510412017 @default.
• W2230151041 countsByYear W22301510412018 @default.
• W2230151041 countsByYear W22301510412019 @default.
• W2230151041 countsByYear W22301510412020 @default.
• W2230151041 countsByYear W22301510412021 @default.
• W2230151041 countsByYear W22301510412023 @default.
• W2230151041 crossrefType "journal-article" @default.
• W2230151041 hasAuthorship W2230151041A5008422091 @default.
• W2230151041 hasAuthorship W2230151041A5019711135 @default.
• W2230151041 hasAuthorship W2230151041A5030769154 @default.
• W2230151041 hasAuthorship W2230151041A5031021734 @default.
• W2230151041 hasAuthorship W2230151041A5032260744 @default.
• W2230151041 hasAuthorship W2230151041A5035100026 @default.
• W2230151041 hasAuthorship W2230151041A5054802858 @default.
• W2230151041 hasAuthorship W2230151041A5059366804 @default.
• W2230151041 hasAuthorship W2230151041A5061219299 @default.
• W2230151041 hasAuthorship W2230151041A5064251341 @default.
• W2230151041 hasAuthorship W2230151041A5085875893 @default.
• W2230151041 hasBestOaLocation W22301510411 @default.
• W2230151041 hasConcept C121608353 @default.
• W2230151041 hasConcept C126322002 @default.
• W2230151041 hasConcept C143998085 @default.
• W2230151041 hasConcept C170493617 @default.
• W2230151041 hasConcept C2776960273 @default.
• W2230151041 hasConcept C2777413986 @default.
• W2230151041 hasConcept C2777583451 @default.
• W2230151041 hasConcept C2778461978 @default.
• W2230151041 hasConcept C2778729363 @default.
• W2230151041 hasConcept C2778820342 @default.
• W2230151041 hasConcept C2779536868 @default.
• W2230151041 hasConcept C42362537 @default.
• W2230151041 hasConcept C71924100 @default.
• W2230151041 hasConceptScore W2230151041C121608353 @default.
• W2230151041 hasConceptScore W2230151041C126322002 @default.
• W2230151041 hasConceptScore W2230151041C143998085 @default.
• W2230151041 hasConceptScore W2230151041C170493617 @default.
• W2230151041 hasConceptScore W2230151041C2776960273 @default.
• W2230151041 hasConceptScore W2230151041C2777413986 @default.
• W2230151041 hasConceptScore W2230151041C2777583451 @default.
• W2230151041 hasConceptScore W2230151041C2778461978 @default.
• W2230151041 hasConceptScore W2230151041C2778729363 @default.
• W2230151041 hasConceptScore W2230151041C2778820342 @default.
• W2230151041 hasConceptScore W2230151041C2779536868 @default.
• W2230151041 hasConceptScore W2230151041C42362537 @default.

• next